![Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States - Cytotherapy Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States - Cytotherapy](https://www.isct-cytotherapy.org/cms/attachment/dd3ed348-79ec-42d9-8d3f-6fdc3aa7b3c2/gr1_lrg.jpg)
Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States - Cytotherapy
![Institutionnalisation du médiateur européen et nouveaux instruments d'enquête : le cas de l'enquête de 2017-2019 sur l'agence européenne des médicaments | Cairn.info Institutionnalisation du médiateur européen et nouveaux instruments d'enquête : le cas de l'enquête de 2017-2019 sur l'agence européenne des médicaments | Cairn.info](https://www.cairn.info/vign_rev/RFAP/RFAP_181.jpg)
Institutionnalisation du médiateur européen et nouveaux instruments d'enquête : le cas de l'enquête de 2017-2019 sur l'agence européenne des médicaments | Cairn.info
The European Medicines Agency (EMA) grants positive opinion for subcutaneous daratumumab in frontline and relapsed/refractory se
![Sensors | Free Full-Text | Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes Sensors | Free Full-Text | Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes](https://www.mdpi.com/sensors/sensors-20-05920/article_deploy/html/images/sensors-20-05920-g001.png)
Sensors | Free Full-Text | Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes
![GlaxoSmithKline's Juluca, Amgen's Repatha and more score EU backing in busy week for CHMP | Fierce Pharma GlaxoSmithKline's Juluca, Amgen's Repatha and more score EU backing in busy week for CHMP | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1521814181/EMA.jpg/EMA.jpg?VersionId=dH6Yx7KPPgv73VhGGZ91uVksENonK4F6)
GlaxoSmithKline's Juluca, Amgen's Repatha and more score EU backing in busy week for CHMP | Fierce Pharma
![Unlocking the EMA Meetings: the Process and How to Prepare Adequately | Voisin Consulting Life Sciences Unlocking the EMA Meetings: the Process and How to Prepare Adequately | Voisin Consulting Life Sciences](https://voisinconsulting.com/wp-content/uploads/2019/11/Ema.jpg)
Unlocking the EMA Meetings: the Process and How to Prepare Adequately | Voisin Consulting Life Sciences
Daniele Focosi, MD PhD MSc on Twitter: "Another failure for molnupiravir…. @theosanderson @PeacockFlu @LongDesertTrain @OliasDave @siamosolocani @ACasadevall1 https://t.co/03A0Ipd8Cc" / Twitter
![SERB reçoit un avis favorable du CHMP pour l'utilisation de Voraxaze® (glucarpidase) en tant que traitement d'urgence de la toxicité du méthotrexate liée à un retard d'élimination SERB reçoit un avis favorable du CHMP pour l'utilisation de Voraxaze® (glucarpidase) en tant que traitement d'urgence de la toxicité du méthotrexate liée à un retard d'élimination](https://mma.prnewswire.com/media/1696654/SERB_Logo.jpg?p=facebook)
SERB reçoit un avis favorable du CHMP pour l'utilisation de Voraxaze® (glucarpidase) en tant que traitement d'urgence de la toxicité du méthotrexate liée à un retard d'élimination
![Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union | Business Wire Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union | Business Wire](https://mms.businesswire.com/media/20220909005519/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union | Business Wire
![Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease](https://mma.prnewswire.com/media/1656864/Chiesi.jpg?p=facebook)